Cytosorbents (HQE1) Stock Statistics & Valuation Metrics

Cytosorbents has a market cap or net worth of CHF19.72M. The enterprise value is $44.10M.

Cytosorbents has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Cytosorbents’s return on equity (ROE) is -1.39 and return on invested capital (ROIC) is -38.77%.

The current PE Ratio of Cytosorbents is ―. Cytosorbents’s PEG ratio is 0.07.

In the last 12 months, Cytosorbents had revenue of 37.06M and earned -8.20M in profits. Earnings per share was -0.13.

In the last 12 months, operating cash flow was -10.07M and capital expenditures -127.76K, giving a free cash flow of -10.20M billion.

Cytosorbents pays an annual dividend of ―, resulting in a dividend yield of ―

Cytosorbents upcoming earnings date is Aug 4, 2026, After Close (Confirmed).

Cytosorbents as a current ratio of 2.13, with Debt / Equity ratio of 864.31%

In the past 12 months, Cytosorbents has paid -401.00K in taxes.

Cytosorbents EV to EBITDA ratio is -14.38, with an EV/FCF ratio of -4.99.

Cytosorbents has CHF4.81M in cash and marketable securities with CHF18.96M in debt, giving a net cash position of -CHF14.15M billion.

Gross margin is 71.01%, with operating margin of -38.42%, and net profit margin of -22.12%.

The average price target for Cytosorbents is CHF0.60, which is 11.43% higher than the current price. The consensus rating is Hold